<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220517054884N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-13</date_registration>
      <primary_sponsor>The University of Qom</primary_sponsor>
      <public_title>Comparison of the effect of methadone and morphine on pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study Intraoperative methadone and morphin for postoperative pain after rhinoseptoplasty</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>182</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63629</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is performed using random block allocation with 4 blocks, which have all four modes A, A, B, B, AA B, B B A A and B A A B A, A B B A, B A A A B, written in 6 cards and The first four patients are randomly grouped. The ward manager takes the patient card out of the bag and the patients are divided into groups by lot. For example, if lottery a A b b The first and second patients are in the first group and the third and fourth patients are in the second group and also for the next four patients, a card is issued again. The anesthesia and injection stage will be performed by an anesthesiologist and The questionnaire is reviewed and completed by an anesthesiologist in the operating room and recovery. 

Describe how to blind, Blinding description: This study is conducted in a double-blind manner, that is, patients, doctors, caregivers, and statistical analysts will not know about the allocation of  groups to reduce bias. In these studies, random assignment is used to allocate patients into two groups: the experimental group  and the control group. Researchers and participants are made aware of who is in which group.

The study will be conducted in  a way that the surgeon, nurses, patients, and the data analyst will not know the type of painkillers injected into the control and intervention groups.  Statistical analyst will be selected from outside the treatment team to ensure double-blindness of the study to a large extent. When the patient is not aware of the type of medicine received, the effect of the patient's personal characteristics and psychological aspect on the research results is reduced. Researchers are unaware of which type of painkillers the participant receives. Therefore, the impact of the doctor's judgments in evaluating the clinical symptoms and the patient's pain after surgery is minimized. By using this method, we try to reduce the effect of possible biases  in the results (the effect of methadone and morphine in reducing pain).</study_design>
      <phase>2-3</phase>
      <hc_freetext>Comparison of the effect of methadone and morphine on pain after rhinoseptoplasty surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: n the main and studied group, the desired dose of the drug is 0.15 mg per body weight (ideal weight). Methadone is administered slowly intravenously half an hour after the start of surgery. Intervention 2: Control group: In this group, the desired dose of the drug is 0.15 mg per body weight (ideal weight). Morphine is administered slowly intravenously half an hour after the start of surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
It can be published as much as possible

When:
Access period starts 6 months after the results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
Results only

Where to obtain:
Dr. Daman Pak Forqani Hospital

How to obtain:
Using the email educationmo110@gmail.com

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Vahid Daman Pak Moghaddam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Forghani Hospital, after the gas station,Azar St</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3714816335</zip>
        <telephone>+98 25 3711 8334</telephone>
        <email>educationmo110@gmail.com</email>
        <affiliation>The University of Qom</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Vahid Daman Pak Moghaddam</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Forghani Hospital,after the gas station,Azar St.</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3714816335</zip>
        <telephone>+98 25 3721 1301</telephone>
        <email>educationmo110@gmail.com</email>
        <affiliation>The University of Qom</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Candidate patients for rhinoseptoplasty surgery
Normal EKG and (no long QT)</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Drug addiction
History and psychological illness
Patient dissatisfaction
History of drug allergy to previous surgeries</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R52</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute Pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: n the main and studied group, the desired dose of the drug is 0.15 mg per body weight (ideal weight). Methadone is administered slowly intravenously half an hour after the start of surgery.</i_keyword>
      <i_keyword>Control group: In this group, the desired dose of the drug is 0.15 mg per body weight (ideal weight). Morphine is administered slowly intravenously half an hour after the start of surgery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain after surgery. Timepoint: The study compares the effect of methadone and morphine on pain after rhinoseptoplasty surgery to measure pain  half an hour after surgery and at the end of surgery , patient extubation and recovery 1 and 6 hours after surgery. Method of measurement: In the study "Comparative study of the effect of methadone and morphine on pain after rhinoseptoplasty surgery" is the method of measuring  the outcome variable using a clinical information checklist and the second  part is the use of a standard pain intensity questionnaire  (Visual Analogue Scale) to determine pain intensity in patients.  The Visual Analogue Scale (VAS) is a subjective measure of pain. It consists of a 10cm line with two endpoints representing ‘no pain’ and ‘worst pain imaginable’. Patients are asked to rate their pain by placing a mark on the line corresponding to their current level of pain. The distance along the line from the ‘no pain’ marker is then measured with a ruler giving a pain score out of 10.</prim_outcome>
      <prim_outcome>Hemodynamic variables. (blood pressure, Saturation of Peripheral Oxygen). Timepoint: The study compares the effect of methadone and morphine on pain after rhinoseptoplasty surgery to measure  Hemodynamic variables half an hour after surgery and at the end of surgery , patient extubation and recovery 1 and 6 hours after surgery. Method of measurement: Mercury sphygmomanometer.( for the measurement of blood pressure ).Pulse Oximeter (for the measurement of Saturation of Peripheral Oxygen).</prim_outcome>
      <prim_outcome>Saturation of Peripheral Oxygen. Timepoint: The study compares the effect of methadone and morphine on pain after rhinoseptoplasty surgery to measure (Saturation of Peripheral Oxygen )half an hour after surgery and at the end of surgery , patient extubation and recovery 1 and 6 hours after surgery. Method of measurement: Pulse Oximeter.</prim_outcome>
      <prim_outcome>Blood pressure. Timepoint: The study compares the effect of methadone and morphine on pain after rhinoseptoplasty surgery to measure (blood pressure  ) half an hour after surgery and at the end of surgery , patient extubation and recovery 1 and 6 hours after surgery. Method of measurement: Mercury sphygmomanometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>In the study "Comparative study of the effect of methadone and morphine on pain after rhinoseptoplasty" the secondary outcome could be "hemodynamic changes". Timepoint: The patient hemodynamics are recorded at the end of the operation, patient extubation and recovery and 1 and 6 hours after surgery. Method of measurement: In this study, using the patient's personal and clinical information checklist, including blood pressure and heart rate and blood oxygen saturation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Qom Medical Sciences Research Deputy</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The University of Qom</source_name>
      <source_name>Qom Medical Sciences Research Deputy</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-12</approval_date>
        <contact_name>Ethics committee of Qom University of Medical Sciences</contact_name>
        <contact_address>Alley 1, Safashahr St. Qom Ghoum Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
